ANGLE PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 19.25 GBX | -6.10% |
|
-17.20% | +63.83% |
| May. 16 | Bens Creek considers administration; Nexxen inks deal | AN |
| May. 16 | ANGLE plc Announces Publication of Study Using the Parsortix System | CI |
| Sales 2023 * | 2.18M 2.77M | Sales 2024 * | 7.47M 9.5M | Capitalization | 50.14M 63.79M |
|---|---|---|---|---|---|
| Net income 2023 * | -19M -24.17M | Net income 2024 * | -14M -17.81M | EV / Sales 2023 * | 17.3 x |
| Net cash position 2023 * | 12.56M 15.98M | Net cash position 2024 * | 1.6M 2.04M | EV / Sales 2024 * | 6.5 x |
| P/E ratio 2023 * |
-2.56
x | P/E ratio 2024 * |
-3.4
x | Employees | - |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 89.26% |
More Fundamentals
* Assessed data
More news
Latest transcript on ANGLE plc
More press releases
| 1 day | -6.10% | ||
| 1 week | -17.20% | ||
| Current month | +40.00% | ||
| 1 month | +54.00% | ||
| 3 months | +11.59% | ||
| 6 months | +97.44% | ||
| Current year | +63.83% |
1 week
19.05
23.70
1 month
13.5025.13
Current year
11.2637.40
1 year
9.0737.40
3 years
9.07163.75
5 years
9.07163.75
10 years
9.07163.75
| Managers | Title | Age | Since |
|---|---|---|---|
Andrew Newland
FOU | Founder | 63 | 94-03-31 |
Ian Griffiths
DFI | Director of Finance/CFO | - | 94-12-31 |
Karen Miller
CTO | Chief Tech/Sci/R&D Officer | - | 23-06-04 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ian Griffiths
DFI | Director of Finance/CFO | - | 94-12-31 |
Andrew Newland
FOU | Founder | 63 | 94-03-31 |
Brian Howlett
BRD | Director/Board Member | 80 | 13-01-06 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-22 | 19.25 | -6.10% | 1,668,626 |
| 24-05-21 | 20.5 | -3.53% | 875,556 |
| 24-05-20 | 21.25 | +3.66% | 688,151 |
| 24-05-17 | 20.5 | -8.89% | 1,887,820 |
| 24-05-16 | 22.5 | -3.23% | 2,392,586 |
Delayed Quote London S.E., May 22, 2024 at 11:35 am EDT
More quotes
ANGLE plc is a United Kingdom-based liquid biopsy company with circulating tumor cell (CTC) solutions for use in research, drug development and clinical oncology using a simple blood sample. Its circulating tumor cell (CTC) harvesting technology known as the Parsortix PC1 System enables complete downstream analysis of the sample, including whole cell imaging and proteomic analysis and full genomic and transcriptomic molecular analysis. The Parsortix PC1 system is a medical device for the capture and harvest of intact CTCs from metastatic breast cancer (MBC) patient blood for user-validated analysis. Its commercial businesses focus on diagnostic products and clinical services. Its diagnostic products include the Parsortix system and associated consumables. Its services include custom made assay development and clinical trial testing for pharma. The Parsortix technology uses a microfluidic technology in the form of a single use cassette to capture and then harvest CTCs from whole blood.
Calendar
2024-06-25
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.1925
GBP
Average target price
0.685
GBP
Spread / Average Target
+255.84%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +63.83% | 63.81M | |
| -20.71% | 17.75B | |
| -42.20% | 2.85B | |
| +21.31% | 1.92B | |
| -5.07% | 1.58B | |
| +34.03% | 1.34B | |
| -17.46% | 952M | |
| -22.39% | 888M | |
| +5.74% | 828M | |
| -27.07% | 611M |
- Stock Market
- Equities
- AGL Stock
